Fig. 1 Change in body weight of tumor-bearing mice
Fig. 2 Change in body weight of tumor-bearing mice
1. Drug type: Novel small molecule
2. Indications: Cancer cachexia
3. Administration route : Oral administration
4. Mechanism of action: This compound significantly inhibits the production and secretion of inflammatory factors and alleviates myasthenia and lipolysis by promoting protein synthesis and inhibiting lipid degradation, improving tumor cachexia.
5. Indications: Cancer cachexia
6. Research progress:
a) The studies in C26 tumor-bearing mice,
i. Significantly inhibit the elevation of TNF-α and IL-6 levels in serum and tumor of C26-bearing mice.
ii. Promote protein synthesis, inhibit lipid degradation and other signaling pathways to alleviate myasthenia and lipolysis and improve tumor cachexia.
b) The studies by head-to-head with anamorelin in vivo show better efficacy in enhancing muscle strength.
c) Preliminary toxicology studies were completed, and the hERG IC50 is 34.1uM, and the therapeutic window is 20 folds
ComboX™ is ACROBiosystems\'s new brand. ComboX™ products include our Streptavidin series products, coated plates, isotype controls for antibody and fusion protein drug research, and general-purpose antibodies.
Emerging VoCs, Omicron, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2， CD133, GPRC5D，CCR8, CCR5, etc.
CD3 proteins and a collection of for bispecific antibody development which are of high specificity and bioactivities and suitable for immunization, antibody screening.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokines including IL families, growth factors, chemokines, TNFs, etc. These products are HEK293 expressed and nearly in authentic structure, high purity and bioactivity, cell based assay/SPR/BLI verified.
To support preclinical/clinical immunogenicity and PK analysis, ACROBiosystems has developed a series of high-affinity anti-idiotypic antibodies. Our pipeline covers five hot targets including adalimum*b, rituxim*b, cetuxim*b, trastuzum*b, and bevacizum*b.
This web search service is supported by Google Inc.